Xiaobing Song
Ganzhou, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
A Triterpenoid-Enriched GLE70 Fraction From Ganoderma lingzhi Ameliorates Alcoholic Liver Disease via Multi-Target Regulation.
Journal: Food science & nutrition
Published: November 25, 2025
Cost-effectiveness of first-line sintilimab plus chemotherapy versus chemotherapy for advanced esophageal carcinoma in China.
Journal: Expert review of pharmacoeconomics & outcomes research
Published: September 27, 2024
Efficacy of oral treprostinil for treating pulmonary arterial hypertension: a systematic review and meta-analysis.
Journal: Postepy w kardiologii interwencyjnej = Advances in interventional cardiology
Published: July 26, 2024
Pembrolizumab combined with chemotherapy versus placebo combined with chemotherapy for HER2-negative advanced gastric cancer in China: a cost-effectiveness analysis.
Journal: Expert review of pharmacoeconomics & outcomes research
Published: July 09, 2024
Cost-effectiveness of nivolumab combined with chemotherapy as a first-line therapy for patients with unresectable or metastatic urothelial carcinoma.
Journal: Therapeutic advances in medical oncology
Published: July 09, 2024
Cost-effectiveness analysis of pembrolizumab plus chemotherapy for patients with recurrent or metastatic cervical cancer in China.
Journal: Current medical research and opinion
Published: February 09, 2023
First-line nivolumab plus ipilimumab for unresectable MPM in China: a cost-effectiveness analysis.
Journal: Orphanet journal of rare diseases
Published: November 30, 2022
First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma: a cost-effectiveness analysis.
Journal: Therapeutic advances in medical oncology
Published: August 09, 2022
Cost-effectiveness of pembrolizumab for second-line treatment of esophageal squamous cell carcinoma patients with a combined positive score of 10 or more.
Journal: Journal of comparative effectiveness research
Published: February 18, 2022
Showing 1-9 of 9
Last Updated: 09/26/2026